PrEP Descovy Oral denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Placed Descovy for PrEP Off-Formulary — and How to Appeal

UnitedHealthcare's formularies tier drugs based on cost and contract status. Descovy (emtricitabine/tenofovir alafenamide) for PrEP may be placed on a non-preferred tier or excluded from formulary on certain UHC plans, typically because a generic tenofovir disoproxil fumarate-based product is available at a lower cost tier. A non-formulary denial or high cost-share is not a clinical determination — it is a cost-management decision — but it can be appealed on medical grounds through a formulary exception process.

### Why This Is Appealable

Most plans subject to the ACA or ERISA are required to have a formulary exception process. A formulary exception can be granted when (a) no formulary drug is clinically appropriate for the member, or (b) a formulary drug has been tried and caused harm or inadequate response, or (c) a clinical reason makes the non-formulary drug the medically necessary choice. For Descovy versus older tenofovir-based PrEP products, clinical reasons may exist based on the patient's individual profile — document them specifically.

Additionally, because PrEP is a USPSTF Grade A preventive service, any cost-sharing — including non-formulary cost-sharing — applied to a qualifying preventive PrEP drug may violate the ACA's preventive-services mandate on plans that must comply with it.

### Your Federal Appeal Rights

• Formulary exception request: File this first — it is often faster than a formal appeal and can be decided in days.
• Internal appeal: Under ERISA §503 or ACA §2719, you have the right to a full internal review if the exception is denied.
• External review: After a final internal denial, request IRO review within approximately four months under ACA §2719.
• Expedited review: If delay would seriously jeopardize your health, expedited decisions are typically required within 72 hours.

### Documentation to Gather

1. Prescriber letter for formulary exception — must state the clinical reason Descovy is medically necessary for this patient over any formulary alternative, referencing patient-specific factors without quoting numeric thresholds. 2. Documentation of any trial of the formulary alternative — if a tenofovir disoproxil fumarate-based product was tried and discontinued, provide dates, reason for discontinuation, and clinical notes. 3. FDA labeling for both Descovy and the formulary alternative — shows the molecular distinction between the tenofovir prodrugs and any safety-profile differences relevant to this patient. 4. UHC formulary exception criteria — download from UHC's website or request from member services. Address every criterion explicitly. 5. ACA preventive-services mandate citation — if the plan is subject to the mandate, note that cost-sharing barriers on USPSTF-recommended PrEP may be independently impermissible.

### Criteria-Mapping Structure

For the exception request and any subsequent appeal, use a table: UHC exception criterion | Clinical basis from chart or prescriber. Make the prescriber letter the anchor document and use the table as a cover sheet. Reviewers process high volumes; a structured, scannable format improves outcomes.

### Next Step

Start with the formulary exception request — it is the fastest path and does not foreclose later appeals. Obtain UHC's formulary exception form from the plan's website or ask the prescriber's office to file it directly. If denied, escalate to formal internal appeal and then external review.